Journal of Research in Ayurvedic Sciences

Register      Login

VOLUME 1 , ISSUE 4 ( October-December, 2017 ) > List of Articles


Clinical Evaluation of Classical Ayurvedic Formulations Simhanada Guggulu and Brihat Saindhavadi Taila in the Management of Rheumatoid Arthritis (Amavata): A Multicentric Open Label Prospective Study

Valiparambil C Deep, Sangeeta Sangvikar, Bhagwan S Sharma, Bhogavalli CS Rao, Bharti, Madan M Padhi

Keywords : Simhanada Guggulu, Brihat saindhavadi taila, Rheumatoid Arthritis,Amavata

Citation Information : Deep VC, Sangvikar S, Sharma B S, Rao BC, B, Padhi MM. Clinical Evaluation of Classical Ayurvedic Formulations Simhanada Guggulu and Brihat Saindhavadi Taila in the Management of Rheumatoid Arthritis (Amavata): A Multicentric Open Label Prospective Study. J Res Ayurvedic Sci 2017; 1 (4):238-246.

DOI: 10.5005/jp-journals-10064-0024

License: CC BY-NC 3.0

Published Online: 00-12-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Introduction: Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory autoimmune disease associated with articular, extra-articular, and systemic effects. Similar symptoms are found in Amavata described in Ayurveda. Simhanada Guggulu and Brihat Saindhavadi Taila are classical formulations that are used commonly in the management of Amavata. Aims and objectives: To assess the clinical efficacy and safety of the classical Ayurvedic formulations Simhanada Guggulu and Brihat Saindhavadi Taila in patients with RA. Materials and methods: A prospective, open label, multicenter study was carried out at two peripheral centers of the Central Council for Research in Ayurvedic Sciences (CCRAS). A total of 111 patients were administered Simhanada Guggulu and Brihat Saindhavadi Taila in the dose of 1.5 gm (3 tablets of 500 mg each) twice daily after food with lukewarm water and local application twice a day respectively, for a period of 12 weeks. Clinical assessment of symptoms, disease activity score-28 (DAS-28), short form 36 (SF-36), and disability index scoring were done at the baseline and at every subsequent visit at an interval of 14 days up to the 12th week and also in the follow-up without medication at the end of the 14th week. Paired sample t-test was used to compare mean change from baseline to 12th and 14th week respectively. Results: At the end of 12 weeks, statistically significant changes in symptoms, DAS 28, SF-36, and disability index score with p-value <0.001 were observed, compared with baseline. No adverse drug reaction (ADR)/adverse events (AEs) were reported during and after the trial. Conclusion: Simhanada Guggulu and Brihat Saindhavadi Taila administered together in the above-mentioned dose were found effective, safe, and tolerable in patients with RA.

PDF Share
  1. Choy E. Understanding the dynamics: pathways included in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012 Jul;51(Suppl 5):v3-v11.
  2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010 Sep;376(9746):1094-1108.
  3. Plenge RM. Rheumatoid arthritis genetics: 2009 update. Curr Rheumatol Rep 2009 Oct;11(5):351-356.
  4. Kobelt, G. The social and economic impact of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatoid arthritis. Philadelphia (PA): Mosby Elsevier; 2009. pp. 83-89.
  5. Srikantha Murthy KR. Madhava Nidanam (roga viniscaya) of Madhavakara (English translation). Chapter 25/6. New Delhi: Chaukhambia Orientalia; 1993.
  6. Simhanada Guggulu—API-Part II. Vol. 2. pp. 130-131.
  7. Brihat Saindhavadi Taila—API-Part II. Vol. 3. pp. 73-76.
  8. Chaturvedi, V.; Ravindran, V.; Thabah, M. Rheumatoid arthritis module–I: clinical features and diagnosis. p. 2.
  9. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017 Jun;76(6):960-977.
  10. Chouhan B, Kumawat RC, Kotecha M, Ramamurthy A, Nathani S. Triphala: a comprehensive ayurveda review. Int J Res Ayurveda Pharm 2013 Jul-Aug;4(4):612-617.
  11. Rasool M, Sabina EP. Antiinflammatory effect of the Indian ayurvedic herbal formulation triphala on adjuvantinduced arthritis in mice. Phytother Res 2007 Sep;21(9):889-894.
  12. Chavan PS, Bhoyar M, Khiyani RM. A critical study on guggulu (Commnifora mukul)—a review. Int J Ayu Alt Med 2015 May-Jun;3(3):159-166.
  13. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986 Jun;18(3-4):407-412.
  14. Sosa S, Tubaro R, Della Loggia R, Bombardelli E. Anti-inflammatory activity of Commiphora mukul extracts. Pharmacol Res 1993;27(Suppl 1):89-90.
  15. Duweiejua M, Zeitlin IJ, Waterman PG, Chapman J, Mhango GJ, Provan GJ. Anti-inflammatory activity of resins from some species of the plant family Burseracea. Planta Med 1993 Feb;59(1):12-16.
PDF Share